ImPuls跨诊断团体运动干预对德国精神科门诊患者的疗效
这项在德国10家门诊康复与医疗机构开展的实用型多中心区组随机3期对照试验,纳入400例符合ICD-10的抑郁、失眠、PTSD、惊恐障碍或广场恐惧症门诊患者,评估为期6个月的跨诊断团体运动干预(ImPuls)联合常规治疗与单纯常规治疗的疗效。
要点
- ImPuls联合常规治疗在6个月时降低总体症状严重度优于单纯常规治疗。
- 两组不良事件无显著差异,仅1例与干预相关的严重不良事件(男性,韧带撕裂)。
核心结论
- ImPuls是门诊精神卫生保健中有效的跨诊断辅助治疗,研究建议将运动疗法作为抑郁、失眠、惊恐障碍、广场恐惧症和PTSD等精神障碍的辅助跨诊断治疗实施。
研究设计与样本
- 实用型、两臂、多中心、区组随机对照3期试验,在德国10家门诊康复与医疗机构开展,按研究地点分层,区组大小为6,分配比1:1,随机序列由外部数据管理者生成,数据收集与管理团队对随机序列设盲。
- 纳入18-65岁、经结构化临床访谈符合ICD-10中度或重度抑郁、原发性失眠、PTSD、惊恐障碍或广场恐惧症之一的门诊患者,需为指定医保参保者、德语流利且无运动医学禁忌。
- 共600例知情同意并接受诊断访谈,199例因纳入排除标准被排除、1例基线评估时撤回同意,最终400例随机分配:ImPuls联合常规治疗组199例,单纯常规治疗组201例。
- 干预为基于证据的户外运动,每次30分钟,目标达到至少中等强度,并包含针对运动行为动机与意志决定因素的行为改变技术;常规治疗代表德国典型门诊医疗,患者可获取任何标准治疗。
- 主要结局为随机化后6个月时以简明症状量表(BSI-18)自评测量的总体症状严重度,在意向治疗样本中分析;安全性在所有参与者中评估;试验注册号DRKS00024152。
主要发现
- 287例(72%)符合中度或重度抑郁标准,81例(20%)符合原发性失眠,37例(9%)符合广场恐惧症,46例(12%)符合惊恐障碍,72例(18%)符合PTSD。
- 38例(19%)参与者未接受最低ImPuls干预剂量。
- 两组不良事件总数或严重不良事件数无显著差异;有1例与干预相关的严重不良事件(男性,韧带撕裂)。
关键数值与推荐
- 干预为每次30分钟户外运动,目标至少中等强度,为期6个月。
- 安全性:两组不良事件总数及严重不良事件数无显著差异,干预相关严重不良事件1例(韧带撕裂)。
临床怎么用
- 对抑郁、失眠、惊恐障碍、广场恐惧症和PTSD门诊患者,可在常规治疗基础上加用跨诊断团体运动干预作为辅助治疗。
- 运动处方可参考每次30分钟、至少中等强度的户外运动,并结合行为改变技术提升动机与坚持性。
- 实施时需评估运动禁忌证并监测不良事件,研究显示整体安全性可接受。
局限性
- 研究未纳入有精神疾病亲身经历者参与研究实施或论文撰写。
- 未采集族裔数据,样本代表性信息有限。
- 19%的干预组参与者未接受最低ImPuls干预剂量,可能影响干预依从性解读。
- 研究在德国特定医保人群与门诊机构开展,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Globally, mental health conditions pose a substantial burden of disease. Despite the availability of evidence-based pharmacological and psychological treatments, the symptoms of a substantial subgroup of patients do not respond to these interventions, and only a minority of patients have access to them. This study aimed to assess the efficacy of ImPuls, a 6-month transdiagnostic group exercise intervention, plus treatment-as-usual, compared with treatment-as-usual alone in outpatients with various mental disorders. METHODS: In this pragmatic, two-arm, multisite, randomised controlled trial in Germany, ten outpatient rehabilitative and medical care facilities were involved as study sites. Participants were outpatients diagnosed according to ICD-10 with one or more of the following disorders based on structured clinical interviews: moderate or severe depression, primary insomnia, post-traumatic stress disorder (PTSD), panic disorder, or agoraphobia. Participants were required to be aged between 18 years and 65 years, insured by the health insurers Allgemeine Ortskrankenkasse Baden-Württemberg or Techniker Krankenkasse, fluent in German, and without medical contraindications for exercise. Blocks of six participants were randomly allocated to ImPuls plus treatment-as-usual or treatment-as-usual alone (allocation ratio: 1:1), stratified by study site. The randomisation sequence was generated by an external data manager. The team responsible for data collection and management was masked to the randomisation sequence. The ImPuls intervention comprised evidence-based outdoor exercises lasting 30 min, and aimed at achieving at least moderate intensity. It also incorporated behavioural change techniques targeting motivational and volitional determinants of exercise behaviour. Treatment-as-usual was representative of typical outpatient health care in Germany, allowing patients access to any standard treatments. The primary outcome was global symptom severity at 6 months after randomisation, measured using self-report on the Brief Symptom Inventory (BSI-18) and analysed in the intention-to-treat sample. No individuals with lived experience of mental illness were involved in conducting the study or writing the final publication. Safety was assessed in all participants. The trial was registered with the German Clinical Trials Register (DRKS00024152) with a completion date of June 30, 2024. FINDINGS: 600 patients provided informed consent, were recruited to the study, and underwent a diagnostic interview between Jan 1, 2021, and May 31, 2022. Following this, 199 were excluded on the basis of inclusion and exclusion criteria and one withdrew consent during the baseline assessment. Of the 400 eligible participants, 284 (71%) self-identified as female, 106 (27%) self-identified as male, and nine (2%) self-identified as other. The mean age was 42·20 years (SD 13·23; range 19-65). Ethnicity data were not assessed. 287 (72%) participants met the criteria for moderate or severe depression, 81 (20%) for primary insomnia, 37 (9%) for agoraphobia, 46 (12%) for panic disorder, and 72 (18%) for PTSD. 199 participants were allocated to the intervention group of ImPuls plus treatment-as-usual and 201 to the control group of treatment-as-usual alone. 38 (19%) participants did not receive the minimum ImPuls intervention dose. ImPuls plus treatment-as-usual demonstrated superior efficacy to treatment-as-usual alone in reducing global symptom severity, with an adjusted difference on BSI-18 of 4·11 (95% CI 1·74-6·48; d=0·35 [95% CI 0·14-0·56]; p=0·0007) at 6 months. There were no significant differences in the total number of adverse events or serious adverse events between the two groups. There was one serious adverse event (male, torn ligament) related to the intervention. INTERPRETATION: ImPuls is an efficacious transdiagnostic adjunctive treatment in outpatient mental health care. Our findings suggest that exercise therapy should be implemented in outpatient mental health care as an adjunctive transdiagnostic treatment for mental disorders such as depression, insomnia, panic disorder, agoraphobia, and PTSD. Transdiagnostic group exercise interventions might ameliorate the existing disparity in care provision between the many individuals in need of evidence-based treatment and the few who are receiving it. FUNDING: The German Innovation Fund of the Federal Joint Committee of Germany.
引用
- Wolf S, Seiffer B, Zeibig JM, et al. A transdiagnostic group exercise intervention for mental health outpatients in Germany (ImPuls): results of a pragmatic, multisite, block-randomised, phase 3 controlled trial. Lancet Psychiatry. 2024. PMID: 38670127. doi:10.1016/S2215-0366(24)00069-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。